Indication: Non-Small Cell Lung Cancer (NSCLC)
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)
Sub-indication: Lung Cancer
Study Type: Drug Study
Principal Investigator: Adam Lye, M.D.Norton Cancer Institute
Sponsor: Sponsor: AstraZeneca
Learn more at ClinicalTrials.gov
Email for more information: Lung-NCIResearch@nortonhealthcare.org